Company intelligence / Profile preview

MetaCure

Ownership: Private
Development stage: Commercial

Overview

MetaCure has developed and clinically tested the DIAMOND System, an implantable device that delivers electrical pulses to the stomach during meals. Clinical trials, including randomized double-blind studies, have demonstrated improvements in glycemic control for overweight patients with type 2 diabetes. The system has received CE mark approval in Europe and completed Phase 3 trials[2][5].

Therapeutic areas: Endocrinology
Modalities: DeviceNon-pharmacological therapy (gastric electrical stimulation)
Industry: Implantable Medical Devices

Drug pipeline

2 assets

GutBiome

Commercial

Indications: Gut health

1 more asset in the full pipeline.

Request access →

Partnerships

Not explicitly listed; clinical collaborations with major academic centers such as Vanderbilt University Medical Center[5]

Beyond the preview

Go deeper on MetaCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MetaCure.

Explore the full profile